Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05007132
Title Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Dominik Paul Modest
Indications

rectum adenocarcinoma

colon adenocarcinoma

colorectal cancer

Therapies

Bevacizumab + Trifluridine-tipiracil hydrochloride

Panitumumab + Trifluridine-tipiracil hydrochloride

Age Groups: adult | senior
Covered Countries DEU

Additional content available in CKB BOOST